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The post-translational modification of the core histones is critical to the regulation of chromatin
structure. Traditional methods for the determination of histone modification utilize immuno-
assay techniques to determine the extent and site of post-translational modification. These
methods, though sensitive, require site-specific antibodies. This manuscript describes the
application of reverse-phase high-pressure liquid chromatography and mass spectrometry
(LC-MS) to analyze global modification levels of core histones. The method is fast, sensitive,
and easily automated. Furthermore, the technique gives the global patterns of modification for
all four core histones in a single experiment. The LC-MS method was optimized using histones
extracted from bovine thymus. These methods were then applied to the characterization of
changes in histone modification in acute myeloid leukemia (AML) cell lines treated with
histone deacetylase (HDAC) inhibitors. Dose-dependent changes in the distribution of
modified core histones were observed. These results were validated in primary leukemia cells
from patients with refractory or relapsed AML or chronic lymphocytic leukemia (CLL) treated
on a Phase I clinical trial of the HDAC inhibitor depsipeptide. An increase in the relative
abundance of specific acetylated forms of histone H4 was readily observable in these patients
at intervals of 4 and 24 h after treatment. (J Am Soc Mass Spectrom 2004, 15, 77–86) © 2004
American Society for Mass Spectrometry
Histones play an important role both in thepackaging of eukaryotic DNA into the nucleusand in regulating the accessibility of that DNA
during cellular processes such as transcription, DNA
replication, DNA repair and recombination. Post-trans-
lational modification of specific residues in the core
histones (acetylation, methylation, phosphorylation,
ADP-ribosylation, and ubiquitination) has been demon-
strated to be critical to their regulatory function [1–8].
Traditional methods for the study of histone post-
translational modifications include micro-sequencing
and immunoassay methods [9, 10]. Micro-sequencing is
tedious and requires relatively large amount of purified
protein. Immunoassays are very sensitive, but rely on
antibodies that recognize different modifications. At
present antibodies are limited to a few well-character-
ized sites of modification (primarily on the N-terminal
tail). The lack of a comprehensive set of antibodies has
limited the systematic analysis of histone modifications.
An additional complication with immunoassay arises
when multiple modifications occur on the same histone.
The simultaneous presence of other modifications may
impact the specificity of antibodies directed at a specific
individual modification. For example, antibodies for the
phosphorylated serine 10 (S10) of histone H3 are
blocked by the presence of an acetylated lysine 14 (K14)
[11, 12].
Mass spectrometry is a powerful technique for the
examination of protein primary structure. The coupling
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of high performance reverse phase liquid chromatogra-
phy (RP-HPLC) and mass spectrometry enables the
determination of the molecular weight of proteins from
complicated mixtures [13–15]. Post-translational modi-
fications alter the molecular weight of the protein
compared with the unmodified protein. These mass
shifts may provide information regarding the identity
and location of the modifications. Besides the advan-
tages of high sensitivity, high mass accuracy and short
experiment time, liquid chromatography mass spectro-
metry (LC-MS) based modification assays can detect
multiple post-translational modifications occurring on a
protein. The simultaneous presence of multiple modifi-
cations does not impact specificity as with antibodies
and thus a better picture of the modification status in
vivo can be determined. More detailed information
related to the location of a specific modification, if
required, can be achieved using peptide mass finger-
printing technique or tandem mass spectrometry.
In this manuscript, we describe the application of
LC-MS for the analysis of global patterns of histone
modification. The method was initially optimized for
the separation and identification of post-translationally
modified histones from bovine thymus tissue. The
method was then used to interrogate the global modi-
fication changes induced by histone deacetylase
(HDAC) inhibitors on histones extracted from human
leukemia cell lines and samples obtained from leukemia
patients.
Experimental
Extraction of Histones
Core histones were extracted from bovine calf thymus
(Worthington Biochemical Corp., Lakewood, NJ) using
acidic extraction methods previously described [16].
Briefly, frozen tissue was thawed in 10 volumes of
buffer A (0.01 M MgCl2, 0.025 M KCl, 0.075 M Tris-HCl,
pH 7.5, 0.05 M NaHSO3, and 0.25 M sucrose (Sigma
Chemical Company, St. Louis, MO) and then homoge-
nized (Polytron Homogenizer Brinkmann Instruments,
Inc., Westbury, NY). The homogenized mixture was
centrifuged for 5 min at 1000 g. The pellet was then
resuspended 2–3 times in buffer A (5–6 times for rat
livers) and centrifuged as described above followed by
five washings with a 0.14 M NaCl solution containing
0.05 M NaHSO3. The pellet was resuspended in 10
volumes of 0.25 M HCl solution and washed for 2 h at
4 °C. The mixture was centrifuged at 27,000 g for 10
min. The supernatant was collected and dialyzed
against 300 volumes of 0.025 M HCl solution for at least
12 h at 4 °C. Core histones were precipitated with 10
volumes of acetone at20 °C for 24 h. The precipitation
was collected, redissolved in water and dried before
HPLC separation.
Preparation of Cell Lines
Kasumi-1 cells (a generous gift of Dr. Michael Caligiuri)
were incubated in RPMI supplemented with 10% of
fetal bovine serum (FBS) at varying concentrations of
depsipeptide (dose range 1 to 10 nmol/L) for 48 h,
washed and resuspended in media before analysis.
Depsipeptide was dissolved in dimethylsulfoxide
(DMSO), and aliquots from this stock were in turn
diluted in media before cell treatment. Pilot studies in
our laboratories showed no biological activity of DMSO
alone compared with depsipeptide (diluted in DMSO),
and therefore this vehicle was not further included as a
negative control.
In addition, four AML cell lines (Kasumi-1, NB-4,
THP-1, and ML-1) (a generous gift of Dr. Michael
Caligiuri) were incubated in RPMI supplemented with
10% of fetal bovine serum (FBS). Aliquots of 2 107cells
were exposed to 1 or 3 mmol/L valproic acid (Sigma
Chemical Company, St. Louis MO) for 48 h, washed
and resuspended in media before analysis. Untreated
cells were used as negative controls. Stock solutions of
valproic acid were prepared in DNase and RNase-free
H2O.
Preparation of Patient Samples
Approval for patient blood collection was obtained
from The Ohio State University Institutional Review
Board for these studies and informed consent was
provided. Cells were procured from patients previously
diagnosed with CLL as defined by the modified NCI
criteria [17]. Normal cells were obtained from leukocyte
reduction filters following blood collection from
healthy volunteers, using the procedure described by
Weitkamp and Crowe [18]. Peripheral blood mononu-
clear cells (PBMC) were isolated utilizing density gra-
dient centrifugation (Ficoll-Paque Plus, Pharmacia Bio-
tech, Piscataway, NJ) and washed in plain RPMI
(Mediatech, Inc., Herndon, VA). CD19 cells were
selected using MACS according to the manufacturer’s
instructions (Miltenyi Biotec Inc., Auburn, CA).
Separation and Identification of Histones
Histones prepared as described above were separated
using reverse phase high-performance liquid chroma-
tography (HP 1100 system, Agilent Technologies, Palo
Alto, CA). Water with 0.1% trifluoroacetic acid and
acetonitrile with 0.1% trifluoroacetic acid were used as
mobile phase A and B. A 20 l aliquot of core histones
(50–100 M) was injected and separated on a C18
column (Supelcosil 4.6  150 mm). The composition of
mobile phase B was increased linearly from 25 to 48% in
2 min, from 48 to 60% from 2–16 min, and maintained at
60% B until 22 min. The column was washed with 100%
B for 1 min and equilibrated with 25% B for 4 min prior
to the next injection. The flow rate was 1 ml min1.
Histones eluted from the column were detected with a
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UV detector at   214 nm. A Micromass Q-TofTM II
(Micromass, Wythenshawe, UK) mass spectrometer
with an orthogonal electrospray source (Z-spray) was
coupled to the outlet of the HPLC using a T-splitter.
Histones were infused into the electrospray source at
the flow rate of about 20 L/min (split ratio 50:1). For
the optimal ESI conditions, capillary voltage was 3000
V, source temperature was 100 °C and cone voltage was
50 V. Data were acquired in continuum mode at the rate
of 1 scan sec1. All spectra were obtained in the positive
ion mode. NaI was used for external mass calibration
over the m/z range 500–2500.
Histone Deacetylase Activity Analysis
Assessment of HDAC enzymatic activity was per-
formed in duplicate using lysates from cells treated
with 1 to 10 nM of depsipetide and compared to
untreated controls, as previously reported [19] Assays
were performed with the use of cell lysates containing
50 g protein, 40 L 10 mM Tris-HCl pH 7.0, plus 1 mM
benzamidine, Sigma protease inhibitor cocktail (1:100
dilution), 1 mM PMSF and 2 mM NaVO4;
3H acetate-
labeled histones extracted from K562 cells at approxi-
mately 1000 cpm; distilled water to a total volume of
200 L. Assay mixtures were centrifuged briefly to
collect components in the bottom of the tube. Incuba-
tions were performed in an Eppendorf Thermomixer at
37 °C at 750 rpm for 3 h. Each reaction was stopped with
the use of 50 L quenching solution (3 M HCl plus 0.6
M glacial acetic acid), and tubes were vortexed. Ethyl
acetate (0.6 mL) was added to each reaction; tubes were
vortexed vigorously for 1 min; samples were then
centrifuged to separate the phases. Radioactivity was
determined in two 200-L aliquots of the ethyl acetate
phase by means of a -counter (Packard Instrument,
Downer’s Grove, IL). Counts per minute were corrected
for extraction efficiency (50%) and reported as a per-
centage of the total counts per minute of 3H histone
added per assay. To provide a positive and a negative
control, HeLa cell lysates incubated with and without
250 mM sodium butyrate were included in all experi-
ments. Samples were assayed in duplicate.
Results and Discussion
Identification of Bovine Histones
The LC-MS results show that the four core histones
(H2A, H2B, H3, and H4) are present in the bovine
thymus extracts. The UV trace and the selected ion
chromatograms for each of the four core histones is
shown in Figure 1. The LC-MS data were deconvoluted
using the MaxEnt method and the average molecular
weight of the histones was determined by the taking the
centroid mass from the deconvoluted isotopic distribu-
tion. As can be seen in the deconvoluted data in Figure
2, the deconvolution algorithm produces artificially
narrow lineshapes that are not indicative of the actual
width of the isotope distributions. Because of this
artifact in processing we are unable to determine if
information regarding minor modifications that overlap
in mass with more abundant modifications was missed.
Such overlaps may occur with oxidation vs. methyl-
ation (16 versus 14 Da) and phosphorylation vs.
diacetylation (80 versus 84 Da). Bovine histones
were identified as the isoforms H2A.1, H2B.1, H3.1, and
H4. Figure 2a shows the observed molecular weight for
H2A (14,002 Da) is closest to the theoretical MW of
H2A.2 (14,003 Da). However, this mass could also
correspond to the monoacetylated form of H2A.1
(13,960 Da  42 Da  14,002 Da). Galasinski et al. [20]
reported that the N-terminal serine of H2A is acety-
lated. Thus, we assume that the peak at 14,002 in our
data is monoacetylated H2A.1. In Figure 2b, the most
abundant peak had a MW of 13,773 Da, corresponding
to the theoretical MW of H2B.1 (13,773 Da). The data
also show that H2B exists as several acetylated and
methylated isoforms. Figure 2c shows the molecular
weight of histone H3 to be 15,275 Da similar to the
theoretical MW for H3.1 which is 15,273 Da. H3 is
heavily methylated as is evident from the 14 Da spacing
between neighboring peaks. Figure 2d shows the spec-
trum for H4. The first detectable peak (11,278 Da) has a
mass shift of 42 Da when compared with the theoretical
MW (11,236 Da) of H4. Therefore, similar to H2A.1, H4
exist modified in vivo as acetylated and methylated
isoforms. The two highest abundance peaks were as-
signed as monoacetyl, dimethyl H4 (11,306 Da) and
diacetyl dimethyl H4 (11,348 Da).
The amount of histone injected onto the column is
estimated to be 2 nmol of total histone extract. The
column used is an analytical reverse phase column that
is split before the electrospray (50:1 split ratio). The
Figure 1. HPLC separation of core histones. (a) The total ion
chromatogram of the reverse phase HPLC purification of bovine
core histones. (b–e) Selected ion chromatograms detected for
individual histones using Q-TOF mass spectrometry. The SICs
showed that histones were separated in the order of H2B, H4,
H2A, and H3.
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advantages of the MS based approach over western
blots are speed, sensitivity and the ability to obtain data
on the global modification for all the core histones in a
single experiment. Typically an LC-MS run is com-
pleted in less than 30 min. In most experiments the
samples are loaded onto an autosampler and are run
unattended. Thus the technique is well suited for adap-
tation to high-throughput clinical screening of histone
modification levels. Global modification levels are de-
termined for all four histones. The identities of the
specific isoforms are not known and thus their differ-
ences in ionization efficiency cannot be determined.
Therefore, the data were regarded as semiquantitative
with respect to the relative abundances of the detected
isoforms.
LC-MS as a Preclinical Assay for Monitoring
HDAC Inhibition
Compounds that manipulate histone post-translational
modification by inhibiting histone deacetylases have
shown promise as potential cancer therapeutics in a
variety of preclinical studies [21–28]. There are several
chemically distinct families of compounds that share
the common property of inhibiting histone deacety-
lases. These compounds include the short chain fatty
acids such as sodium butyrate and phenylbutyrate,
hydroxamic acids such as trichostatin A (TSA) and
cyclic tetrapeptides such as depsipeptide (FR901228).
Treatment of cells with any of these compounds results
in the accumulation of highly acetylated isoforms of the
histones, which in turn results in gene expression, cell
differentiation and apoptosis [21–28].
Recently, the HDAC inhibitor depsipeptide has been
shown to induce these biological effects in KASUMI-1
cells, an acute myeloid cell line carrying the t(8;21), [29,
30]. At the molecular level the t(8;21) results in AML1/
ETO, a fusion gene that encodes a chimeric protein
shown to aberrantly recruit histone deacetylase activity
on target genes important for normal hematopoiesis
[30–33]. The changes in histone H4 modification in-
duced by the treatment of Kasumi-1 cells with dep-
sipeptide were characterized immunologically using
antibodies that recognize specific sites of acetylation
[30]. Depsipeptide treatment resulted in a dramatic
increase in acetylation of histone H4 lysines 5, 8, and 12,
with only a modest effect on lysine 16. This pattern of
changes in histone acetylation is similar to that seen
upon deletion of the yeast HDAC Rpd3p [10, 34, 35],
suggesting that this compound is likely to be a specific
inhibitor of the related human class I HDAC’s (HDAC
1-3) [36–39]. In an effort to validate LC-MS as a reliable
method for assessing histone post-translational modifi-
cations, we analyzed histone changes occurring in Ka-
sumi-1 cells treated with varying concentration of de-
spipeptide (0, 1, 5, and 10 nM) as compared to baseline.
Figure 3 shows the LC-MS obtained modification
patterns for H4 extracted from Kasumi-1 cells treated
with depsipetide. In these tissue culture experiments, 20
to 50 million cells yielded 0.5 ml of histone solution for
Figure 2. Deconvoluted ESI mass spectra of histones extracted from bovine thymus. They are
identified from the top to bottom as H2A.1, H2B.1, H3.1, and H4.
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gel and mass spectrometry analysis. In untreated cells,
the most abundant peak in the H4 deconvoluted spec-
trum is monoacetly, dimethyl H4 (11,306 Da). Other
peaks were assigned as the following isoforms: mono-
acetyl H4 (11,279 Da), monoacetyl, monomethyl H4
(11,292 Da), diacetyl H4 (11,320 Da), diacetyl, mono-
methyl H4 (11,334 Da), diacetyl, dimethyl H4 (11,348
Da, second most abundance peak), triacetyl H4 (11,362
Da), triacetyl, monomethyl H4 (11,377 Da), triacetyl,
dimethyl H4 (11,391 Da). No significant change in
modification was observed upon addition of 1 nM
depsipeptide. The most abundant peak is still the
monoacetyl-dimethyl-H4 (11,306 Da). However, a slight
increase in the abundance of diacetyl-dimethyl-H4
(11,350 Da) as well as other peaks at higher mass was
observed. Significant changes in the modification pat-
tern were observed when the cell lines were treated
with higher depsipeptide concentrations. The modifica-
tion pattern of H4 following 5 nM depsipeptide treat-
ment shifted to significantly higher mass. The most
abundant peak in this spectrum was observed at 11,348
Da, representing the diacetyl, dimethyl H4. The relative
abundance of peaks with positive mass difference of N
 42 Da (compared with the diacetyl, dimethyl H4)
represents the most abundant species in the spectra.
The 42 Da spacing of these peaks suggests an increase in
acetylation due to the inhibition of HDACs by dep-
sipeptide.
Inhibition was more significant when the cell line
was treated at the highest concentration of depsipep-
tide. Figure 3 shows the deconvoluted spectrum of H4
from cell lines after the addition of 10 nM depsipeps-
tide. The spectrum showed the H4 modification pattern
shifted toward even higher mass. The most abundant
peak in this spectrum is still the diacetyl-dimethyl-H4
(11,348 Da). Again the trend of peaks at increasingly
higher mass separated by 42 Da was observed. The
dose-dependent increases in the relative proportion of
highly acetylated H4 isoforms correlate with inhibition
of HDAC enzymatic activity and correspond to the
doses of depsipeptide that are cytotoxic to Kasumi-1
cells [30, 40].
The MS based analysis was also performed on four
different cell lines treated with valproic acid. The cells
lines were: KAS-1, NB-4 [41, 42], ML-1 [43] and THP-1
[44, 45]. Data for acetylation of H4 are represented in
Figure 4. Valproic acid has traditionally been used in
the treatment of mood disorders and epilepsy but has
recently been shown to have significant HDAC inhibi-
tory activity, which perhaps mediates its anti-cancer
activity [46, 47]. For histone H4 the most abundant
species was again the monoacetyl, dimethyl isoform.
Histone H4 hyperacetylation levels occurred in all four
cell lines upon treatment with the HDAC inhibitor,
valproic acid. The relative abundance of the mono-
acetyl, dimethyl isoform versus the concentration of
valproic acid was plotted for each of the four cell lines
(Figure 5). Concurrently, a uniform decrease in the
relative concentration of the monoacetylated, dimethy-
lated isoform was also observed. This relative decrease
is likely due to the presence of higher mass isoforms
Figure 3. Dose-dependent inhibition of HDAC activity by depsipeptide in AML1/ETO-positive
Kasumi-1 cells. Increasing H4 acetylation was observed in the ESI mass spectra as the concentration
of depsipeptide was increased as shown on the left. The increasing acetylation correlates with a
decrease in HDAC activity as shown on the right.
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being generated because of the inhibition of the
deacetylation.
A slight change in the histone acetylation for H3,
H2A and H2B was observed in valproic acid-treated
cells, with the exception being the ML-1 cell line.
Treatment of histone H2A with valproic acid showed
hyperacetylation, Figure 6. The dashed line indicates
the decrease in the relative abundance of the unmodi-
fied isoform that correlates with an increase in the
abundance of the monacetyl and diacetyl isoforms. Of
note, a dose dependent inhibition of HDAC activity was
demonstrated for each of the cell lines analyzed (Mar-
cucci, unpublished results).
LC-MS as a Clinical Assay for Histone
Modification Levels
While the previous data demonstrate that LC-MS is a
valuable technique for the characterization of histone
post-translational modifications in a human tissue cul-
ture model, it is important determine whether these
Figure 4. HDAC inhibition by valproic acid at concentrations of 0 mM, 1 mM, 3 mM for the NB-4,
ML-1, KAS-1, and THP-1 cell lines. Increasing H4 acetylation was observed as the concentration of
valproic acid was increased.
Figure 5. Plot of the relative concentration of the dimethy
monacetyl isoform of histone H4 versus valproic acid concentra-
tion for the NB-4, ML-1, KAS-1, and THP-1 cell lines.
Figure 6. Plot of the relative concentration of the unmodified
isoform of histone H2A versus valproic acid concentration for the
NB-4, ML-1, KAS-1, and THP-1 cell lines.
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methods can be extended to the analysis of human
patient samples. We analyzed histone modification pro-
files of CD19 B cells from three normal volunteers and
three CLL patients. The data for histone H2A given in
Figure 7a shows the LC-MS profiles of histone H2A
from the three normal individuals. In these plots, pro-
Figure 8. Deconvoluted ESI mass spectra of histone H4 from a patient with CLL (left) and a patient
with AML (right) participating in a Phase I clinical trial of the HDAC inhibitor depsipeptide. Samples
were taken 1 week prior to treatment, immediately before treatment, 4 and 24 h after treatment. An
increase in the histone acetylation can be seen in the 4 and 24 h samples.
Figure 7. Deconvoluted ESI mass spectra of histone H2A from three human volunteers (a), three
patients will CLL (b), and a single patient with AML (c). The data show a possible correlation between
histone acetylation and CLL.
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tein isoforms are represented by peaks in which the
molecular mass is given on the X-axis and the abun-
dance is determined by the area of the peak. While
histone H2A can be modified on several different amino
acids, this protein existed as only three major isoforms
in all three individuals. The peak at 14,003 (measure-
ments have an error of 2–3 mass units) is the unmod-
ified form of H2A while the peaks at 14,017 and 14,046
represent monomethylated (theoretical m of 14 Da)
and monoacetylated (theoretical m of 42 Da) H2A
respectively. The profile of histone H2A from each of
these individuals is remarkably similar, with some
variability seen in the relative abundance of the mono-
acetylated isoform. The LC-MS analysis of histone H2A
from three CLL patient samples is shown in Figure 7b.
Again, the same three major isoforms are present but
the amount of monoacetylated H2A is dramatically
reduced in all three of the CLL samples, suggesting that
decreased H2A acetylation may correlate with the CLL
phenotype. This difference in H2A acetylation may not
be a general property of leukemic cells. As seen in
Figure 7c, LC-MS analysis of histone H2A from a
patient with acute myeloid leukemia (AML) shows a
normal level of H2A acetylation. A systematic and
quantitative analysis of each of the core histones from a
large number of both normal and CLL samples will
allow us to determine whether differences in histone
post-translational modifications, such as that seen here
for histone H2A, are associated with CLL.
As an integral part of a Phase I trial of depsipetpide,
inhibition of HDAC enzymatic activity and histone
post-translational modifications were assessed in leuke-
mia cells collected from patients treated on this protocol
[19]. Both histone post-translational modification and
HDAC inhibition were easily detected within four h of
treatment with depsipeptide in vitro, before the earliest
events of apoptosis (i.e., annexin binding to cell surface)
were evident. Western Blots, were used to demonstrate
that depsipeptide-induced specific changes in the pat-
terns of acetylation on histones H3 and H4. However, as
discussed above, the use of modification-specific anti-
bodies provides a limited amount of information con-
cerning the modification state of the histones. We
therefore employed mass spectrometry to complement
the information gained from the immunological analy-
sis and characterize in greater molecular detail the
changes in histone modification induced by depsipep-
tide in the Phase I clinical trial.
Figure 8 shows the LC-MS analysis of histone H4
isolated from samples obtained from a CLL and AML
patient enrolled in the depsipeptide Phase I trial. For
these studies, 20 to 50 million cells were obtained both
pre- and post-treatment. The identities of the prominent
H4 isoforms (assuming N-terminal acetylation) are as
follows: 11,292—monomethyl; 11,306—dimethyl;
11,320—monoacetyl; 11,334 – monoacetyl/monometh-
yl; 11,348 – monoacetyl/dimethyl; 11,362—diacetyl;
11,390—triacetyl/dimethyl. Samples were obtained one
week prior to, and just before, treatment as indicated.
The modification profile of histone H4 in these two
samples was strikingly similar, demonstrating the sta-
bility of an individual’s histone modification status over
Figure 9. Plot of the relative concentrations for each of the N-terminal acetylated isoforms of H4
versus the time the sample was taken for a patient with CLL (left) and a patient with AML (right)
participating in a Phase 1 clinical trial of the HDAC inhibitor depsipeptide. The plot reveals that the
dimethylated isoforms undergo the most significant change in both the CLL and AML patient.
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time and, importantly, the reproducibility of our ana-
lytical methods. At 4 and 24 h post-treatment, a redis-
tribution of the H4 modification profile is apparent.
These changes were quantitated by determining the
area of each peak as a percentage of the total histone H4
present. The changes can be more easily distinguished
when the percent total of each isoform is plotted versus
the treatment time as shown in Figure 9. Surprisingly,
the mono-, di-, and triacetylated isoforms of histone H4
do not increase dramatically following HDAC inhibitor
treatment. Rather, virtually all of the increase in histone
H4 acetylation resulting from depsipeptide treatment
occurred on the subpopulation of histone H4 that was
dimethylated. This type of detailed information is sim-
ply impossible to obtain using the immunological meth-
ods now commonly employed in the field. Understand-
ing the basis for the selective effect of an HDAC
inhibitor such as depsipeptide on a subset of histone
molecules will contribute to both understanding the
mechanisms by which this important class of agents
impacts cell growth as well as developing HDAC
specific agents that effectively alter these changes.
Conclusion
Liquid chromatography and mass spectrometry were
used to identify and quantitate changes in histone
modification levels. The LC-MS technique has the fol-
lowing advantages over immunoassays: (1) Modifica-
tion patterns are obtained simultaneously for all four
core histones, (2) the observed abundance of specific
histone isoforms are not affected by the presence of
multiple modifications, (3) requires very small amount
of sample (10–20 g/injection), and (4) short analysis
time (30 min). The method is particularly useful for
monitoring changes in histone modifications that occur
during tumorigenesis. For example, the changes in
histone modification induced by the potentially thera-
peutic HDAC inhibitors, depsipeptide and valproic
acid, were determined. The data clearly indicate that
histone acetylation is increased upon treatment with
these HDAC inhibitors. This effect is easily observed by
monitoring the increase in higher mass isoforms that
correspond to the addition of acetyl groups (M  42
Da). The technique has the sensitivity to examine his-
tone modification levels in a clinical setting for patients
undergoing treatment with HDAC inhibitors.
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